Stereotactic Body Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Observational Study from a Regional Cancer Center in South Asia—A Case Series

Abstract Introduction Concurrent chemoradiation is the treatment of choice for unresectable locally advanced pancreatic cancer (LAPC). Recent progress toward an effective chemotherapeutic regime has seen improvement in systemic control; however, local control remains a significant issue. One strategy to improve local control and survival is stereotactic body radiotherapy (SBRT). Objectives This study aims to describe the clinical and treatment characteristics of patients with unresectable LAPC treated with SBRT and to assess the outcome. Material and Methods This is a retrospective observation study of case series involving patients treated with SBRT from January 2015 to December 2023 with unresectable LAPC. Data were recorded from the electronic medical records of the hospital-based cancer registry, and overall survival was calculated using the Statistical Package for the Social Sciences software. Result We enrolled four patients in this study. This group consisted of four patients with unresectable LAPC who were treated with the FOLFORINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) chemotherapy regime followed by SBRT. For most patients, the radiotherapy dose was 30 to 40 Gy five times per week. These patients exhibited no acute or late toxicity, with 5 to 18 months overall survival. Conclusion Chemotherapy followed by SBRT is an effective treatment in unresectable LAPC besides chemoradiation.